UBS Optimus Foundation Deutschland

9 April 2025 PureTech Health plc PureTech Appoints Peel Hunt as Joint UK Corporate Broker PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.   For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh. Contact: PureTech Public Relations publicrelations@puretechhealth.com Investor Relations IR@puretechhealth.com END NRAUPUWWCUPAPGR

Hotly anticipated late-stage data for Pfizer and Arvinas' oral oestrogen receptor-degrader vepdegestrant (ARV-471) debuted on Tuesday, with positive results seen in breast cancer patients with an ESR1 mutation. However, the drug failed to demonstrate benefit in those without the mutation, sending Arvinas shares down as much as 50%.While a number of oral selective oestrogen receptor degraders (SERDs) have delivered similarly mixed data — such as Menarini's Orserdu (elacestrant) and Eli Lilly's imlunestrant — hopes were high for vepdegestrant in the broader population. UBS analysts recently said "we think the potential for success in ESR1 [wild type] patients is greater than appreciated" for vepdegestrant, partially due to the design of the VERITAC-2 study.The trial enrolled 624 patients with oestrogen receptor-positive, HER2-negative advanced or metastatic breast cancer whose disease progressed following prior treatment with CDK 4/6 inhibitors and endocrine therapy. Participants were randomised to receive once-daily vepdegestrant or fulvestrant.PFS exceeded targetTop-line results showed that in patients with an ESR1 mutation, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant, meeting the trial's primary endpoint in this population. Pfizer and Arvinas noted that PFS exceeded the pre-specified target hazard ratio of 0.60 in this group.However, the companies said that in the wider trial population, which also included those with ESR1 wild type, the study failed to reach statistical significance on improvement in PFS.OS data immaturePfizer and Arvinas noted that less than a quarter of the required number of events have occurred for the overall survival (OS) analysis — a key secondary endpoint — with the study continuing in order to evaluate this goal."The first Phase III data readout for a PROTAC degrader represents a significant achievement and these data show that vepdegestrant has the potential to provide clinically meaningful outcomes for…patients with metastatic breast cancer whose tumours harbour [ESR1] mutations," remarked John Houston, CEO at Arvinas. The companies noted that the data will be shared with global regulatory authorities, and presented at a medical conference later this year. Meanwhile, the Phase III VERITAC-3 study investigating vepdegestrant in combination with Pfizer's CDK 4/6 inhibitor Ibrance (palbociclib) in the first-line setting is also ongoing.Back in 2021, Pfizer paid $650 million upfront for rights to co-develop vepdegestrant, which utilises Arvinas' PROTAC (PROteolysis TArgeting Chimera) protein degrader platform.The VERITAC-2 results Tuesday follow a positive Phase III readout for AstraZeneca's oral SERD candidate camizestrant last month, showing a significant PFS benefit when paired with a CDK4/6 inhibitor in first-line patients with HR+/HER2- advanced breast cancer whose tumours have an emergent ESR1 mutation. In a recent interview with FirstWord to discuss the SERENA-6 study, key opinion leader Azka Ali described the results as a win-win for both safety and efficacy, and would likely hasten the shift from aromatase inhibitors to oral SERDs in patients with ESR1 mutations. For the rest of that conversation, see – KOL Views Q&A: Battle for oral SERD supremacy in HR+ breast cancer boils down to efficacy.

AstraZeneca and Daiichi Sankyo have unveiled new data on their TROP2-directed ADC in pretreated lung cancer patients with EGFR-mutated disease, adding to their case for a potential US approval. In the pooled analysis from two non-small cell lung cancer trials — the Phase 2 TROPION-Lung05 and the failed Phase 3 TROPION-Lung01 — datopotamab deruxtecan (Dato-DXd) produced a 42.7% confirmed objective response rate in the subgroup of 117 patients with EGFR-mutated disease. The ADC also reached seven months median duration of response and 5.8 months median progression-free survival in those patients, according to AstraZeneca’s presentation at ESMO Asia in Singapore. The EGFR-mutated population represents about 20% of all lung cancer patients, the company said. The latest data reveal comes less than a month after the UK drugmaker and Daiichi pulled their FDA filing for Dato-DXd in nonsquamous NSCLC, replacing it with a submission for the smaller EGFR-mutated population in response to the agency’s feedback. Back in May, the TROPION-Lung01 study failed to meet one of its dual primary endpoints of overall survival. Meanwhile, the open-label TROPION-Lung05 trial achieved a 35.8% confirmed ORR in its primary endpoint, according to results presented at last year’s ESMO Congress. AstraZeneca and Daiichi are touting Dato-DXd as a potential successor to their blockbuster breast cancer drug Enhertu. In September 2023, the ADC met a co-primary endpoint in a Phase 3 study in patients with previously-treated inoperable or metastatic HR-positive, HER2-negative breast cancer. In February, UBS analysts said Dato-DXd could reach $2.5 billion in peak sales. The UK drugmaker’s TROPION development program includes 17 studies covering various types and settings of lung and breast cancer.